Form 4: Kiora Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Lisa Walters-Hoffert, a director of Kiora Pharmaceuticals, acquired stock options for 20,000 shares on April 1, 2025.
Summary
- Lisa Walters-Hoffert, a director at Kiora Pharmaceuticals, acquired stock options on April 1, 2025.
- The options are for 20,000 shares of common stock.
- The exercise price of the options is $2.93.
- The options vest on April 1, 2026, and expire on April 1, 2035.
- Following the transaction, Walters-Hoffert directly owns options for 20,000 shares.
Sentiment
Score: 5
Explanation: This is a neutral event. It reflects standard compensation practices and doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a standard regulatory filing related to insider transactions. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The transaction could have a minor impact on shareholders by potentially diluting the stock if the options are exercised in the future.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of the stock option transaction. |
| 04/01/2026 | Date the stock options become fully exercisable. |
| 04/01/2035 | Expiration date of the stock options. |
| 04/02/2025 | Date of the Form 4 filing. |
Keywords
stock options, Form 4, director, Kiora Pharmaceuticals, insider trading, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.